Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer. - Archive ouverte HAL Access content directly
Journal Articles Supportive Care in Cancer Year : 2006

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.

(1) , (1, 2) , (3) , (3) , (1, 3) , (4) , (5) , (3, 6) , (1)
1
2
3
4
5
6

Abstract

INTRODUCTION: Anaemia is a common toxicity in cancer patients and epoetins (EPOs) are now an established treatment. The economic profile of EPO treatment was assessed in patients with breast cancer treated by adjuvant-chemotherapy. MATERIALS AND METHODS: Two strategies were compared: without treatment by EPO and with the possible use of treatment by EPO (epoetin alfa) when required. The clinical effectiveness criterion was time adjusted to quality of life and economic data included only direct medical costs. MAIN RESULTS: One hundred ninety-two patients were included. In the group with the strategy containing the possible use of EPO, 45.5% of patients effectively received EPO. A significant difference in the haemoglobin level profile over time was observed which provided a significant overall benefit of 0.0052 (p<10(-4)) quality-adjusted life year (QALY) associated with an extra cost of 1,615 (p<10(-4)). In the base case analysis, the cost per added QALY was estimated as 310,577 with the strategy containing the possible use of EPO. CONCLUSION: This robust result seems to be unacceptable, but the only relevant point of discussion might be the level of acceptable incremental cost-effectiveness ratio (ICER) for a patient.

Dates and versions

inserm-00473467 , version 1 (15-04-2010)

Identifiers

Cite

Philippe Fagnoni, Samuel Limat, Loïc Chaigneau, Emmanuel Guardiola, Stéphanie Briaud, et al.. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.. Supportive Care in Cancer, 2006, 14 (10), pp.1030-7. ⟨10.1007/s00520-006-0062-5⟩. ⟨inserm-00473467⟩
75 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More